ArticleCureus2025
A Case of Refractory Hidradenitis Suppurativa Successfully Treated With Upadacitinib.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Severe ectopic hidradenitis suppurativa refractory to adalimumab.JAAD case reports · 2026Article
- Article
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic, disabling inflammatory disease with a high unmet medical need, characterized by persistent, painful skin nodules, abscesses, and draining tunnels. Research on HS is rapidly evolving, with a variety of agents with different mechanisms of action being developed. As several Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways are involved in the pathogenesis of HS, JAK inhibitors represent a promising therapeutic target. Herein, we present a case of severe hidradenitis suppurativa treated with upadacitinib following the failure of adalimumab and secukinumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.